{"transactions":[{"id":1113595,"issuer":{"id":7875,"kind":"organization","name":"FibroBiologics, Inc.","symbol":"FBLG"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T19:20:53.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual meeting."}],"balance_after":22000,"derivative":{"exercise_price":0.8725,"expiration_date":"2025-06-11","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001641172-25-014931","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814150/000164117225014931/ownership.xml","form_type":"4"}},{"id":1422033,"issuer":{"id":7875,"kind":"organization","name":"FibroBiologics, Inc.","symbol":"FBLG"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-27T19:51:52.000Z","date":"2024-08-27","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual meeting."}],"balance_after":5000,"derivative":{"exercise_price":1.73,"expiration_date":"2034-08-26","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001493152-24-034066","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814150/000149315224034066/ownership.xml","form_type":"4"}},{"id":1650451,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF BUSINESS OFFICER"}}],"security":"Restricted Stock Unit","published_at":"2024-02-12T16:44:41.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":39293,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each RSU granted on or after the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was converted into a grant of restricted stock unit awards in respect of a number of shares of AbbVie common stock equal to the number of shares of Common Stock underlying such RSU as of immediately prior to the Effective Time multiplied by 0.18, and otherwise with the same terms and conditions that were applicable immediately prior to the Effective Time."},{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each RSU granted on or after the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was converted into a grant of restricted stock unit awards in respect of a number of shares of AbbVie common stock equal to the number of shares of Common Stock underlying such RSU as of immediately prior to the Effective Time multiplied by 0.18, and otherwise with the same terms and conditions that were applicable immediately prior to the Effective Time."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each RSU granted on or after the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was converted into a grant of restricted stock unit awards in respect of a number of shares of AbbVie common stock equal to the number of shares of Common Stock underlying such RSU as of immediately prior to the Effective Time multiplied by 0.18, and otherwise with the same terms and conditions that were applicable immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each RSU granted on or after the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was converted into a grant of restricted stock unit awards in respect of a number of shares of AbbVie common stock equal to the number of shares of Common Stock underlying such RSU as of immediately prior to the Effective Time multiplied by 0.18, and otherwise with the same terms and conditions that were applicable immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each RSU granted on or after the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was converted into a grant of restricted stock unit awards in respect of a number of shares of AbbVie common stock equal to the number of shares of Common Stock underlying such RSU as of immediately prior to the Effective Time multiplied by 0.18, and otherwise with the same terms and conditions that were applicable immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":39293},"source":{"system":"sec-edgar","filing":"0001104659-24-014711","document":"tm245865-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014711/tm245865-11_4seq1.xml","form_type":"4"}},{"id":1650450,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF BUSINESS OFFICER"}}],"security":"Restricted Stock Unit","published_at":"2024-02-12T16:44:41.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":28700,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit (\"RSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of common stock, par value $.01 per share, of the Issuer (\"Common Stock\") subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit (\"RSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of common stock, par value $.01 per share, of the Issuer (\"Common Stock\") subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit (\"RSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of common stock, par value $.01 per share, of the Issuer (\"Common Stock\") subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit (\"RSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of common stock, par value $.01 per share, of the Issuer (\"Common Stock\") subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit (\"RSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of common stock, par value $.01 per share, of the Issuer (\"Common Stock\") subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":28700},"source":{"system":"sec-edgar","filing":"0001104659-24-014711","document":"tm245865-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014711/tm245865-11_4seq1.xml","form_type":"4"}},{"id":1650449,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF BUSINESS OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-12T16:44:41.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":65000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."}],"balance_after":0,"derivative":{"exercise_price":4.92,"expiration_date":"2030-06-01","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001104659-24-014711","document":"tm245865-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014711/tm245865-11_4seq1.xml","form_type":"4"}},{"id":1650448,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF BUSINESS OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-12T16:44:41.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":258195,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."}],"balance_after":0,"derivative":{"exercise_price":4.66,"expiration_date":"2033-02-03","underlying":"Common Stock","underlying_shares":258195},"source":{"system":"sec-edgar","filing":"0001104659-24-014711","document":"tm245865-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014711/tm245865-11_4seq1.xml","form_type":"4"}},{"id":1650447,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF BUSINESS OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-12T16:44:41.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":303465,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."}],"balance_after":0,"derivative":{"exercise_price":5.32,"expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":303465},"source":{"system":"sec-edgar","filing":"0001104659-24-014711","document":"tm245865-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014711/tm245865-11_4seq1.xml","form_type":"4"}},{"id":1650446,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF BUSINESS OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-12T16:44:41.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":150610,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."}],"balance_after":0,"derivative":{"exercise_price":7.69,"expiration_date":"2031-02-05","underlying":"Common Stock","underlying_shares":150610},"source":{"system":"sec-edgar","filing":"0001104659-24-014711","document":"tm245865-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014711/tm245865-11_4seq1.xml","form_type":"4"}},{"id":1650445,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2024-02-12T16:44:41.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":73274,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation (\"AbbVie\"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie (\"Intermediate Sub\"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub (\"Purchaser\"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each share of common stock, par value $.01 per share, of the Issuer (the \"Common Stock\"), that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive an amount in cash equal to $31.26, without interest (the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation (\"AbbVie\"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie (\"Intermediate Sub\"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub (\"Purchaser\"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each share of common stock, par value $.01 per share, of the Issuer (the \"Common Stock\"), that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive an amount in cash equal to $31.26, without interest (the \"Merger Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-24-014711","document":"tm245865-11_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014711/tm245865-11_4seq1.xml","form_type":"4"}},{"id":1657517,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF BUSINESS OFFICER"}}],"security":"Restricted Stock Unit","published_at":"2024-02-06T21:47:10.000Z","date":"2024-02-02","kind":"exercise","planned":true,"acquired":false,"shares":14350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs were awarded on 2/3/2023 and vest over a three-year period, with 33 1/3% of the RSUs vesting on each of the first three anniversaries of the date of grant, subject to continued service through each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs were awarded on 2/3/2023 and vest over a three-year period, with 33 1/3% of the RSUs vesting on each of the first three anniversaries of the date of grant, subject to continued service through each vesting date."}],"balance_after":28700,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":14350},"source":{"system":"sec-edgar","filing":"0001415889-24-002873","document":"form4-02072024_020202.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588924002873/form4-02072024_020202.xml","form_type":"4"}},{"id":1657516,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2024-02-06T21:47:10.000Z","date":"2024-02-05","kind":"sale","planned":true,"acquired":false,"shares":4583,"price":29.3,"value":134281.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on June 15, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":73274,"source":{"system":"sec-edgar","filing":"0001415889-24-002873","document":"form4-02072024_020202.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588924002873/form4-02072024_020202.xml","form_type":"4"}},{"id":1657515,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2024-02-06T21:47:10.000Z","date":"2024-02-02","kind":"exercise","planned":true,"acquired":true,"shares":14350,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":77857,"source":{"system":"sec-edgar","filing":"0001415889-24-002873","document":"form4-02072024_020202.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588924002873/form4-02072024_020202.xml","form_type":"4"}},{"id":1659952,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF BUSINESS OFFICER"}}],"security":"Restricted Stock Unit","published_at":"2024-02-05T21:26:22.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":39293,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vest over a three-year period, with 33 1/3% of the RSUs vesting on each of the first three anniversaries of the date of grant, subject to continued service through each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vest over a three-year period, with 33 1/3% of the RSUs vesting on each of the first three anniversaries of the date of grant, subject to continued service through each vesting date."}],"balance_after":39293,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":39293},"source":{"system":"sec-edgar","filing":"0001415889-24-002761","document":"form4-02062024_020214.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588924002761/form4-02062024_020214.xml","form_type":"4"}},{"id":1694998,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF BUSINESS OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-03T17:51:50.000Z","date":"2023-12-29","kind":"exercise","planned":false,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on February 4, 2022 and is exercisable as to 25% on the first year anniversary of the grant and 6.25% quarterly for the subsequent three years."}],"balance_after":303465,"derivative":{"exercise_price":5.32,"expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001415889-24-000381","document":"form4-01032024_100137.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588924000381/form4-01032024_100137.xml","form_type":"4"}},{"id":1694997,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2024-01-03T17:51:50.000Z","date":"2023-12-29","kind":"grant","planned":false,"acquired":true,"shares":367,"price":16.01,"value":5875.67,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These shares were purchased due to participation by the reporting individual in the ImmunoGen Employee Stock Purchase Plan (the ESPP). It pertains to the ESPP purchase period from July 1, 2023 through December 31, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on July 3, 2023"}],"balance_after":63507,"source":{"system":"sec-edgar","filing":"0001415889-24-000381","document":"form4-01032024_100137.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588924000381/form4-01032024_100137.xml","form_type":"4"}},{"id":1694996,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2024-01-03T17:51:50.000Z","date":"2023-12-29","kind":"exercise","planned":false,"acquired":true,"shares":30000,"price":5.32,"value":159600.0,"ownership":{"direct":true},"balance_after":63140,"source":{"system":"sec-edgar","filing":"0001415889-24-000381","document":"form4-01032024_100137.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588924000381/form4-01032024_100137.xml","form_type":"4"}},{"id":1722809,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2023-12-05T21:08:03.000Z","date":"2023-11-30","kind":"sale","planned":true,"acquired":false,"shares":3826,"price":29.2,"value":111719.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 10, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":33140,"source":{"system":"sec-edgar","filing":"0001415889-23-015909","document":"form4-12062023_021256.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923015909/form4-12062023_021256.xml","form_type":"4"}},{"id":1737888,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF BUSINESS OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-17T19:52:55.000Z","date":"2023-11-17","kind":"exercise","planned":true,"acquired":false,"shares":76023,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 10, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on February 5, 2021 and is exercisable as to 25% on the first year anniversary of the grant and 6.25% quarterly for the subsequent three years."}],"balance_after":76787,"derivative":{"exercise_price":7.69,"expiration_date":"2031-02-05","underlying":"Common Stock","underlying_shares":76023},"source":{"system":"sec-edgar","filing":"0001415889-23-015268","document":"form4-11182023_121148.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923015268/form4-11182023_121148.xml","form_type":"4"}},{"id":1737887,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF BUSINESS OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-17T19:52:55.000Z","date":"2023-11-17","kind":"exercise","planned":true,"acquired":false,"shares":2200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 10, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on June 1, 2020 and is exercisable as to 25% on the first year anniversary of the grant and 6.25% quarterly for the subsequent three years."}],"balance_after":48823,"derivative":{"exercise_price":4.92,"expiration_date":"2030-06-01","underlying":"Common Stock","underlying_shares":2200},"source":{"system":"sec-edgar","filing":"0001415889-23-015268","document":"form4-11182023_121148.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923015268/form4-11182023_121148.xml","form_type":"4"}},{"id":1737886,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF BUSINESS OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-17T19:52:55.000Z","date":"2023-11-16","kind":"exercise","planned":true,"acquired":false,"shares":900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 10, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on February 5, 2021 and is exercisable as to 25% on the first year anniversary of the grant and 6.25% quarterly for the subsequent three years."}],"balance_after":152810,"derivative":{"exercise_price":7.69,"expiration_date":"2031-02-05","underlying":"Common Stock","underlying_shares":900},"source":{"system":"sec-edgar","filing":"0001415889-23-015268","document":"form4-11182023_121148.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923015268/form4-11182023_121148.xml","form_type":"4"}},{"id":1737885,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF BUSINESS OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-17T19:52:55.000Z","date":"2023-11-16","kind":"exercise","planned":true,"acquired":false,"shares":3200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 10, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on June 1, 2020 and is exercisable as to 25% on the first year anniversary of the grant and 6.25% quarterly for the subsequent three years."}],"balance_after":51023,"derivative":{"exercise_price":4.92,"expiration_date":"2030-06-01","underlying":"Common Stock","underlying_shares":3200},"source":{"system":"sec-edgar","filing":"0001415889-23-015268","document":"form4-11182023_121148.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923015268/form4-11182023_121148.xml","form_type":"4"}},{"id":1737884,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF BUSINESS OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-17T19:52:55.000Z","date":"2023-11-15","kind":"exercise","planned":true,"acquired":false,"shares":5300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 10, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on February 5, 2021 and is exercisable as to 25% on the first year anniversary of the grant and 6.25% quarterly for the subsequent three years."}],"balance_after":153710,"derivative":{"exercise_price":7.69,"expiration_date":"2031-02-05","underlying":"Common Stock","underlying_shares":5300},"source":{"system":"sec-edgar","filing":"0001415889-23-015268","document":"form4-11182023_121148.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923015268/form4-11182023_121148.xml","form_type":"4"}},{"id":1737883,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF BUSINESS OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-17T19:52:55.000Z","date":"2023-11-15","kind":"exercise","planned":true,"acquired":false,"shares":20986,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 10, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on June 1, 2020 and is exercisable as to 25% on the first year anniversary of the grant and 6.25% quarterly for the subsequent three years."}],"balance_after":54223,"derivative":{"exercise_price":4.92,"expiration_date":"2030-06-01","underlying":"Common Stock","underlying_shares":20986},"source":{"system":"sec-edgar","filing":"0001415889-23-015268","document":"form4-11182023_121148.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923015268/form4-11182023_121148.xml","form_type":"4"}},{"id":1737882,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2023-11-17T19:52:55.000Z","date":"2023-11-17","kind":"sale","planned":true,"acquired":false,"shares":78223,"price":16.05,"value":1255479.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 10, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.17, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges."}],"balance_after":36966,"source":{"system":"sec-edgar","filing":"0001415889-23-015268","document":"form4-11182023_121148.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923015268/form4-11182023_121148.xml","form_type":"4"}},{"id":1737881,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2023-11-17T19:52:55.000Z","date":"2023-11-17","kind":"exercise","planned":true,"acquired":true,"shares":76023,"price":7.69,"value":584616.87,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 10, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":115189,"source":{"system":"sec-edgar","filing":"0001415889-23-015268","document":"form4-11182023_121148.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923015268/form4-11182023_121148.xml","form_type":"4"}},{"id":1737880,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2023-11-17T19:52:55.000Z","date":"2023-11-17","kind":"exercise","planned":true,"acquired":true,"shares":2200,"price":4.92,"value":10824.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 10, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":39166,"source":{"system":"sec-edgar","filing":"0001415889-23-015268","document":"form4-11182023_121148.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923015268/form4-11182023_121148.xml","form_type":"4"}},{"id":1737879,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2023-11-17T19:52:55.000Z","date":"2023-11-16","kind":"sale","planned":true,"acquired":false,"shares":4100,"price":16.01,"value":65641.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 10, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.02, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges."}],"balance_after":36966,"source":{"system":"sec-edgar","filing":"0001415889-23-015268","document":"form4-11182023_121148.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923015268/form4-11182023_121148.xml","form_type":"4"}},{"id":1737878,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2023-11-17T19:52:55.000Z","date":"2023-11-16","kind":"exercise","planned":true,"acquired":true,"shares":900,"price":7.69,"value":6921.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 10, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":41066,"source":{"system":"sec-edgar","filing":"0001415889-23-015268","document":"form4-11182023_121148.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923015268/form4-11182023_121148.xml","form_type":"4"}},{"id":1737877,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2023-11-17T19:52:55.000Z","date":"2023-11-16","kind":"exercise","planned":true,"acquired":true,"shares":3200,"price":4.92,"value":15744.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 10, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":40166,"source":{"system":"sec-edgar","filing":"0001415889-23-015268","document":"form4-11182023_121148.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923015268/form4-11182023_121148.xml","form_type":"4"}},{"id":1737876,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2023-11-17T19:52:55.000Z","date":"2023-11-15","kind":"sale","planned":true,"acquired":false,"shares":26286,"price":16.01,"value":420838.86,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 10, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.03, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges."}],"balance_after":36966,"source":{"system":"sec-edgar","filing":"0001415889-23-015268","document":"form4-11182023_121148.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923015268/form4-11182023_121148.xml","form_type":"4"}},{"id":1737875,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2023-11-17T19:52:55.000Z","date":"2023-11-15","kind":"exercise","planned":true,"acquired":true,"shares":5300,"price":7.69,"value":40757.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 10, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":63252,"source":{"system":"sec-edgar","filing":"0001415889-23-015268","document":"form4-11182023_121148.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923015268/form4-11182023_121148.xml","form_type":"4"}},{"id":1737874,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2023-11-17T19:52:55.000Z","date":"2023-11-15","kind":"exercise","planned":true,"acquired":true,"shares":20986,"price":4.92,"value":103251.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 10, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":57952,"source":{"system":"sec-edgar","filing":"0001415889-23-015268","document":"form4-11182023_121148.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923015268/form4-11182023_121148.xml","form_type":"4"}},{"id":1784210,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF BUSINESS OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-09-11T16:08:50.000Z","date":"2023-09-08","kind":"exercise","planned":false,"acquired":false,"shares":26006,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Exercisable as to 25% on the first year anniversary of the grant and 6.25% quarterly for the subsequent three years."}],"balance_after":159010,"derivative":{"exercise_price":7.69,"exercise_date":"2022-02-05","expiration_date":"2031-02-05","underlying":"Common Stock","underlying_shares":26006},"source":{"system":"sec-edgar","filing":"0001415889-23-013144","document":"form4-09112023_080942.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923013144/form4-09112023_080942.xml","form_type":"4"}},{"id":1784209,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2023-09-11T16:08:50.000Z","date":"2023-09-08","kind":"exercise","planned":false,"acquired":true,"shares":26006,"price":7.69,"value":199986.14,"ownership":{"direct":true},"balance_after":36966,"source":{"system":"sec-edgar","filing":"0001415889-23-013144","document":"form4-09112023_080942.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923013144/form4-09112023_080942.xml","form_type":"4"}},{"id":1810343,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF BUSINESS OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-11T17:02:31.000Z","date":"2023-08-09","kind":"exercise","planned":false,"acquired":false,"shares":100210,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 25% on the first year anniversary of the grant and 6.25% quarterly for the subsequent three years."}],"balance_after":75209,"derivative":{"exercise_price":4.92,"exercise_date":"2021-06-01","expiration_date":"2030-06-01","underlying":"Common Stock","underlying_shares":100210},"source":{"system":"sec-edgar","filing":"0001415889-23-012146","document":"form4-08112023_090823.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923012146/form4-08112023_090823.xml","form_type":"4"}},{"id":1810342,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2023-08-11T17:02:31.000Z","date":"2023-08-09","kind":"sale","planned":false,"acquired":false,"shares":100210,"price":14.2,"value":1422982.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.97 to $14.46, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges."}],"balance_after":10960,"source":{"system":"sec-edgar","filing":"0001415889-23-012146","document":"form4-08112023_090823.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923012146/form4-08112023_090823.xml","form_type":"4"}},{"id":1810341,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2023-08-11T17:02:31.000Z","date":"2023-08-09","kind":"exercise","planned":false,"acquired":true,"shares":100210,"price":4.92,"value":493033.2,"ownership":{"direct":true},"balance_after":111170,"source":{"system":"sec-edgar","filing":"0001415889-23-012146","document":"form4-08112023_090823.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923012146/form4-08112023_090823.xml","form_type":"4"}},{"id":1815465,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF BUSINESS OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-04T19:33:10.000Z","date":"2023-08-04","kind":"exercise","planned":false,"acquired":false,"shares":80326,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Exercisable as to 25% on the first year anniversary of the grant and 6.25% quarterly for the subsequent three years."}],"balance_after":175419,"derivative":{"exercise_price":4.92,"exercise_date":"2021-06-01","expiration_date":"2030-06-01","underlying":"Common Stock","underlying_shares":80326},"source":{"system":"sec-edgar","filing":"0001415889-23-011882","document":"form4-08042023_110803.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923011882/form4-08042023_110803.xml","form_type":"4"}},{"id":1815464,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF BUSINESS OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-04T19:33:10.000Z","date":"2023-08-02","kind":"exercise","planned":false,"acquired":false,"shares":4255,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Exercisable as to 25% on the first year anniversary of the grant and 6.25% quarterly for the subsequent three years."}],"balance_after":255745,"derivative":{"exercise_price":4.92,"exercise_date":"2021-06-01","expiration_date":"2030-06-01","underlying":"Common Stock","underlying_shares":4255},"source":{"system":"sec-edgar","filing":"0001415889-23-011882","document":"form4-08042023_110803.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923011882/form4-08042023_110803.xml","form_type":"4"}},{"id":1815463,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2023-08-04T19:33:10.000Z","date":"2023-08-04","kind":"sale","planned":false,"acquired":false,"shares":80326,"price":17.05,"value":1369558.3,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.00 to $17.12, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges."}],"balance_after":10960,"source":{"system":"sec-edgar","filing":"0001415889-23-011882","document":"form4-08042023_110803.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923011882/form4-08042023_110803.xml","form_type":"4"}},{"id":1815462,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2023-08-04T19:33:10.000Z","date":"2023-08-04","kind":"exercise","planned":false,"acquired":true,"shares":80326,"price":4.92,"value":395203.92,"ownership":{"direct":true},"balance_after":91286,"source":{"system":"sec-edgar","filing":"0001415889-23-011882","document":"form4-08042023_110803.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923011882/form4-08042023_110803.xml","form_type":"4"}},{"id":1815461,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2023-08-04T19:33:10.000Z","date":"2023-08-02","kind":"sale","planned":false,"acquired":false,"shares":4255,"price":18.12,"value":77100.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.01 to $18.15, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges."}],"balance_after":10960,"source":{"system":"sec-edgar","filing":"0001415889-23-011882","document":"form4-08042023_110803.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923011882/form4-08042023_110803.xml","form_type":"4"}},{"id":1815460,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2023-08-04T19:33:10.000Z","date":"2023-08-02","kind":"exercise","planned":false,"acquired":true,"shares":4255,"price":4.92,"value":20934.6,"ownership":{"direct":true},"balance_after":15215,"source":{"system":"sec-edgar","filing":"0001415889-23-011882","document":"form4-08042023_110803.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923011882/form4-08042023_110803.xml","form_type":"4"}},{"id":1838229,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2023-07-05T17:55:52.000Z","date":"2023-06-30","kind":"grant","planned":false,"acquired":true,"shares":3792,"price":4.05,"value":15357.6,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These shares were purchased due to participation by the reporting individual in the ImmunoGen Employee Stock Purchase Plan (the ESPP). It pertains to the ESPP purchase period from January 1, 2023 through June 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 3, 2023."}],"balance_after":10960,"source":{"system":"sec-edgar","filing":"0001415889-23-010825","document":"form4-07052023_090749.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923010825/form4-07052023_090749.xml","form_type":"4"}},{"id":2029511,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF BUSINESS OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-07T17:21:25.000Z","date":"2023-02-03","kind":"grant","acquired":true,"shares":245900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the date of grant, and thereafter an additional 6.25% of the shares vesting on each succeeding quarterly anniversary of the date of grant."}],"balance_after":245900,"derivative":{"exercise_price":4.66,"expiration_date":"2033-02-03","underlying":"Common Stock","underlying_shares":245900},"source":{"system":"sec-edgar","filing":"0001415889-23-002105","document":"form4-02072023_100207.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923002105/form4-02072023_100207.xml","form_type":"4"}},{"id":2029510,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF BUSINESS OFFICER"}}],"security":"Restricted Stock Unit","published_at":"2023-02-07T17:21:25.000Z","date":"2023-02-03","kind":"grant","acquired":true,"shares":41000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vest over a three-year period, with 33 1/3% of the RSUs vesting on each of the first three anniversaries of the date of grant, subject to continued service through each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vest over a three-year period, with 33 1/3% of the RSUs vesting on each of the first three anniversaries of the date of grant, subject to continued service through each vesting date."}],"balance_after":41000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":41000},"source":{"system":"sec-edgar","filing":"0001415889-23-002105","document":"form4-02072023_100207.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923002105/form4-02072023_100207.xml","form_type":"4"}},{"id":2076354,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF BUSINESS OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-27T17:18:12.000Z","date":"2022-11-14","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On June 1, 2020, the reporting person was granted an option to purchase 120,000 shares of common stock. The option vests in installments upon the satisfaction of certain performance criteria. On November 14, 2022, certain performance criteria were met, resulting in the vesting of 50% of the performance stock option award."}],"balance_after":90000,"derivative":{"exercise_price":4.92,"exercise_date":"2022-11-14","expiration_date":"2030-06-01","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001415889-22-012996","document":"form4-12272022_101257.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588922012996/form4-12272022_101257.xml","form_type":"4"}},{"id":2076353,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF BUSINESS OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-27T17:18:12.000Z","date":"2022-05-20","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 1, 2020, the reporting person was granted an option to purchase 120,000 shares of common stock. The option vests in installments upon the satisfaction of certain performance criteria. On May 20, 2022, certain performance criteria were met, resulting in the vesting of 25% of the performance stock option award."}],"balance_after":30000,"derivative":{"exercise_price":4.92,"exercise_date":"2022-05-20","expiration_date":"2030-06-01","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001415889-22-012996","document":"form4-12272022_101257.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588922012996/form4-12272022_101257.xml","form_type":"4"}},{"id":2215876,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2022-07-05T16:33:03.000Z","date":"2022-06-30","kind":"grant","acquired":true,"shares":3342,"price":3.825,"value":12783.15,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These shares were purchased due to participation by the reporting individual in the ImmunoGen Employee Stock Purchase Plan (the ESPP). It pertains to the ESPP purchase period from January 1, 2022 through June 30, 2022"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on June 30, 2022"}],"balance_after":7168,"source":{"system":"sec-edgar","filing":"0001415889-22-007337","document":"form4-07052022_010742.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588922007337/form4-07052022_010742.xml","form_type":"4"}},{"id":2409132,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Business Officer"}}],"security":"Common Stock (right to buy)","published_at":"2022-02-08T17:26:10.000Z","date":"2022-02-04","kind":"grant","acquired":true,"shares":333465,"price":5.32,"value":1774033.8,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest over a four-year period, with 25% of the shares vesting on the one year anniversary of the date of grant, and thereafter an additional 6.25% of the shares vesting on each succeeding quarterly anniversary of the date of grant."}],"balance_after":333465,"derivative":{"exercise_price":5.32,"exercise_date":"2023-02-04","expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":333465},"source":{"system":"sec-edgar","filing":"0001179110-22-000925","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911022000925/edgar.xml","form_type":"4"}},{"id":2452171,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Business Officer"}}],"security":"Common Stock","published_at":"2022-01-04T16:06:24.000Z","date":"2021-12-31","kind":"grant","acquired":true,"shares":1496,"price":5.6,"value":8377.6,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These shares were purchased due to participation by the reporting individual in the ImmunoGen Employee Stock Purchase Plan (the ESPP). It pertains to the ESPP purchase period from July 1, 2021 through December 31, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on July 1, 2021."}],"balance_after":3826,"source":{"system":"sec-edgar","filing":"0001179110-22-000102","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911022000102/edgar.xml","form_type":"4"}},{"id":2646301,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-07-02T16:20:44.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":2330,"price":5.52,"value":12861.6,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These shares were purchased due to participation by the reporting individual in the ImmunoGen Employee Stock Purchase Plan (the ESPP). It pertains to the ESPP purchase period from January 1, 2021 through June 30, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 4, 2021."}],"balance_after":2330,"source":{"system":"sec-edgar","filing":"0001179110-21-007316","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911021007316/edgar.xml","form_type":"4"}},{"id":2873082,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock (right to buy)","published_at":"2021-02-09T20:11:00.000Z","date":"2021-02-05","kind":"grant","acquired":true,"shares":185016,"price":7.69,"value":1422773.04,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest over a four-year period, with 25% of the shares vesting on the one year anniversary of the date of grant, and thereafter an additional 6.25% of the shares vesting on each succeeding quarterly anniversary of the date of grant."}],"balance_after":185016,"derivative":{"exercise_price":7.69,"exercise_date":"2022-02-05","expiration_date":"2031-02-05","underlying":"Common Stock","underlying_shares":185016},"source":{"system":"sec-edgar","filing":"0001179110-21-001494","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911021001494/edgar.xml","form_type":"4"}},{"id":3122680,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":78566,"kind":"person","name":"Coen Stacy Ann","position":1,"cik":"0001814150","reported_name":"Coen Stacy Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock (right to buy)","published_at":"2020-06-04T13:09:12.000Z","date":"2020-06-01","kind":"grant","acquired":true,"shares":260000,"price":4.92,"value":1279200.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest over a four-year period, with 25% of the shares vesting on the one year anniversary of the date of grant, and thereafter an additional 6.25% of the shares vesting on each succeeding quarterly anniversary of the date of grant."}],"balance_after":260000,"derivative":{"exercise_price":4.92,"exercise_date":"2021-06-01","expiration_date":"2030-06-01","underlying":"Common Stock","underlying_shares":260000},"source":{"system":"sec-edgar","filing":"0001179110-20-006966","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911020006966/edgar.xml","form_type":"4"}}]}